Summary
The successful introduction of angiotensin converting enzyme (ACE) inhibitors in the treatment of patients with essential hypertension or heart failure has increased interest in the (patho)physiological role of the renin-angiotensin system (RAS). ACE is not only involved in the formation of angiotensin II from angiotensin I, but also inactivates vasoactive substances such as bradykinin and substance P. Accumulation of these substances during treatment with ACE inhibitors may contribute to both their therapeutic action and certain adverse effects associated with their use, such as cough and angioneurotic oedema.
Renin inhibitors offer an alternative approach to inhibit the RAS. The major advantage of these, still experimental, drugs is their high specificity for the RAS since angiotensinogen is the only known substrate of renin. The currently available renin inhibitors are pseudopeptides that are rapidly taken up by the liver and excreted in the bile. Consequently, these drugs are subjected to a considerable first pass effect which limits their oral bioavailability. Additionally, plasma elimination half-life times are short and the duration of action is limited. Despite these shortcomings, single oral or intravenous administration results in a 80 to 90% inhibition of plasma renin activity and a slight reduction in blood pressure in patients with hypertension. The extent of blood pressure reduction is dependent on the patient's salt balance .
After I week of oral treatment with the renin inhibitor remikiren, the antihypertensive effect was reduced in salt-repleted hypertensive patients . Subsequent intravenous administration of the drug did not further affect blood pressure, indicating that it was not the first pass effect that was limiting the efficacy of remikiren. The reactive increase in immunoreactive renin, alternative routes of angiotensin II formation and counteracting blood pressure regulating mechanisms may also be involved in the limited haemodynamic response to renin inhibitors. . m from the circulation. This is probably the case for renin since it has rapid access to the extravascular space where it can be trapped by renin-binding proteinsp,8] Apart from extraction from the circulation, local production of renin in the heart, kidneys and the vascular wall has been demonstrated by molecular techniques. Also for angiotensinogen and ACE, local production has been observed in the important effector organs of the RAS.l9] At present, the primary site of angiotensin I formation is thought to be in the extravascular compartment.U'l'
The relevance of this phenomenon is that measurement of circulating renin or angiotensin II does not necessarily reflect the amount of angiotensin II at the receptor level. Indeed, differences between plasma and cardiac angiotensin II formation have been observed in animal models of congestive heart failure .!'!' ACE is not only involved in the formation of angiotensin II, but also metabolises substances like
The Renin-Angiotensin System
The renin-angiotensin system (RAS) plays an important role in cardiovascular function and regulation of water and salt excretion. Angiotensin II is the effector molecule of the RAS system . Angiotensin II is a potent vasoconstrictor, mediates renal sodium reabsorption, has growth stimulating properties, and stimulates aldosterone and vasopressin release from the adrenal cortex and hypophysis, respectively. Angiotensin II is formed by enzymatic breakdown of angiotensinogen. Several enzymes are involved in this conversion of which renin and the angiotensin converting enzyme (ACE) are probably the most important ( fig . 1) . [1] Renin catalyses the formation of angiotensin I from angiotensinogen. Indeed , at present angiotensinogen is the only known substrate of renin . ACE catalyses the formation of angiotensin II from angiotensin I. The functional significance of the other enzymes that are able to catalyse the formation of angiotensin II is not exactly known.
The renin-mediated conversion of angiotensinogen to angiotensin I is the rate-limiting step of the RAS and the plasma level of renin is increased in conditions of an activated sympathetic nervous system, hypovolaemia, salt depletion and reduced intrarenal blood pressure. Circulating renin primarily originates from the kidney, where it is released from the juxtaglomerular cells,l2-4] Circulating renin is primarily eliminated by the liver and to a lesser extent by the kidney .I1,5] Circulating angiotensinogen originates from the liver.l 6 ] ACE is primarily formed in the pulmonary vascular bed, but it is also formed in other vascular beds. The essential components of the RAS (i.e, angiotensinogen, renin and ACE) are not only present in blood but also in the vascular wall and in several organs , including the heart and the kidneys.
Components of the tissue RAS may originate
